Glen Eagle Advisors LLC Has $2.42 Million Stock Position in Stryker Co. (NYSE:SYK)

Glen Eagle Advisors LLC raised its stake in Stryker Co. (NYSE:SYK) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,719 shares of the medical technology company’s stock after acquiring an additional 178 shares during the quarter. Glen Eagle Advisors LLC’s holdings in Stryker were worth $2,419,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Capital & Planning LLC increased its position in Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 29 shares in the last quarter. Grove Bank & Trust boosted its stake in shares of Stryker by 43.4% in the 4th quarter. Grove Bank & Trust now owns 175 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 53 shares during the last quarter. Sky Investment Group LLC boosted its stake in shares of Stryker by 0.6% in the 4th quarter. Sky Investment Group LLC now owns 15,204 shares of the medical technology company’s stock valued at $5,474,000 after purchasing an additional 85 shares during the last quarter. Addenda Capital Inc. boosted its stake in shares of Stryker by 0.9% in the 4th quarter. Addenda Capital Inc. now owns 18,914 shares of the medical technology company’s stock valued at $6,823,000 after purchasing an additional 160 shares during the last quarter. Finally, Regent Peak Wealth Advisors LLC bought a new position in shares of Stryker in the 4th quarter valued at about $204,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a research note on Monday, May 5th. JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada lifted their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $427.05.

Stryker Price Performance

Shares of SYK opened at $389.30 on Wednesday. The company has a market cap of $148.59 billion, a price-to-earnings ratio of 50.17, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company’s fifty day simple moving average is $367.75 and its 200 day simple moving average is $375.89. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.50 earnings per share. On average, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s dividend payout ratio is currently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.